JAK inhibitor with a vitamin D analog for treatment of skin diseases

A pharmaceutical formulation for topical treatment of a skin disease, comprising (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) a vitamin D3 analog, or a pharmaceutically acceptable salt thereof, wherein the JAK inhibitor, or a pharmaceutically acceptable salt thereof, is a JAK1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof;

• and the vitamin D3 analog, or a pharmaceutically acceptable salt thereof, is a compound of Formula (II):
• wherein:
• R1 is H or OH;
• R2 and R3 are each H;
• or
• R2 is O—R2A;
• and R3 is H;
• or
• R2 and R3 are taken together to form a ═CH2 group;
• R2A is —C1-4 alkylene-OH;
• R4 and R5 are each H;
• or
• R4 and R5 are taken together to form a ═CH2 group;
• R6 and R7 are each H;
• or
• R6 and R7 are taken together to form a ═CH2 group;
• L is —CH2—CH2—CH(R12)—, —CH2—CH2—CH2—CH(R12)—, —CH═CH—CH(R12)—, —CH═CH—CH═CH—, —CH2—C≡C—, —O—CH2—CH2—, or —O—CH2—CH2—CH2—, wherein R12 is H or OH;
• R9 is C1-3 alkyl or C1-4 haloalkyl;
• R10 is C1-3 alkyl or C1-4 haloalkyl;
• R11 is H or OH;
• or, alternatively, R9 and R10 together with the carbon atom to which they are attached form a C3-4 cycloalkyl ring;
• and
• R11 is H.